Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regul

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the anal

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfol

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a O

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are

Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Ki

Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partner

Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), today announced

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in

Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session.

Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular s

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.ht

Major M&A deals this week include: New Mountail Capital buys Asset Living, SalesForce acquires C

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicate

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Ja

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Per

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jas

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the anal

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (J

Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Ja

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 wee

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 wee

Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8 th a

Jasper Therapeutics, Inc. (NASDAQ: JSPR - Get Free Report)'s share price traded down 7.3% on Monday.

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary

Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic ast

MDB: 24% | MongoDB shares are trading higher after the company reported better-than-expected Q3 fina

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Ja

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized sha

Shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR - Get Free Report) have received an average recomm

New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor ri

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors th

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Per

JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term chal